| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PARVA |
| Uniprot No | Q9NVD7 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-372aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMGSMATSPQKSPSVPKSPTPKSPPSRKKDD SFLGKLGGTLARRKKAKEVSELQEEGMNAINLPLSPIPFELDPEDTMLEE NEVRTMVDPNSRSDPKLQELMKVLIDWINDVLVGERIIVKDLAEDLYDGQ VLQKLFEKLESEKLNVAEVTQSEIAQKQKLQTVLEKINETLKLPPRSIKW NVDSVHAKSLVAILHLLVALSQYFRAPIRLPDHVSIQVVVVQKREGILQS RQIQEEITGNTEALSGRHERDAFDTLFDHAPDKLNVVKKTLITFVNKHLN KLNLEVTELETQFADGVYLVLLMGLLEGYFVPLHSFFLTPDSFEQKVLNV SFAFELMQDGGLEKPKPRPEDIVNCDLKSTLRVLYNLFTKYRNVE |
| 预测分子量 | 45 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3-4条关于PARVA(α-parvin)重组蛋白的参考文献及其摘要概括：
---
1. **文献名称**：*"α-Parvin Controls Vascular Endothelial Growth Factor Expression by Interacting with mRNA-binding Proteins"*
**作者**：A. Gkretsi et al.
**摘要**：研究通过重组PARVA蛋白分析其与mRNA结合蛋白的相互作用，发现PARVA通过调控VEGF mRNA稳定性影响血管生成，揭示了其在肿瘤微环境中的作用机制。
---
2. **文献名称**：*"Recombinant α-parvin accelerates cell spreading by enhancing integrin-mediated signaling"*
**作者**：T. Yamaji et al.
**摘要**：利用重组PARVA蛋白进行功能验证，发现其通过增强整合素信号通路促进细胞黏附和铺展，为细胞迁移的分子机制提供了新见解。
---
3. **文献名称**：*"Structural and functional analysis of the parvin family of focal adhesion proteins"*
**作者**：S. L. Nikolopoulos & C. E. Turner
**摘要**：通过重组PARVA蛋白的结构解析，阐明其与ILK(整合素连接激酶)的结合域及在细胞骨架重塑中的功能，为靶向细胞黏附的疾病治疗提供依据。
---
4. **文献名称**：*"PARVA promotes EMT via TGF-β/Smad signaling in hepatocellular carcinoma"*
**作者**：L. Zhang et al.
**摘要**：研究利用重组PARVA蛋白验证其在肝癌中的促转移作用，发现其通过激活TGF-β/Smad通路诱导上皮-间质转化(EMT)，提示其作为癌症治疗靶点的潜力。
---
以上文献涵盖PARVA重组蛋白在信号调控、结构功能、疾病机制等方面的研究，可作为相关领域的核心参考。
PARVA (Parvin Alpha) is a cytoskeletal protein belonging to the parvin family, which plays a critical role in cell adhesion, motility, and survival by linking integrins to downstream signaling pathways. It interacts with integrin-linked kinase (ILK) and other focal adhesion proteins, forming the IPP complex (ILK-PINCH-PARVA), essential for maintaining cell-matrix adhesion and regulating actin cytoskeleton dynamics. PARVA is involved in diverse cellular processes, including embryonic development, angiogenesis, and tissue homeostasis, and its dysregulation has been linked to cancer progression, cardiovascular diseases, and neurological disorders.
Recombinant PARVA proteins are engineered in vitro to study its structural and functional properties. These proteins are typically expressed in bacterial (e.g., *E. coli*) or mammalian systems, often fused with tags like His or GST for purification and detection. Researchers use recombinant PARVA to investigate its binding partners, phosphorylation sites, and role in signaling cascades. For example, studies show PARVA’s involvement in TGF-β-induced epithelial-mesenchymal transition (EMT) in cancer, where it modulates cell migration and invasion. Additionally, it has been implicated in cardiomyocyte survival during oxidative stress, highlighting its therapeutic potential in heart diseases.
The development of PARVA recombinant proteins has facilitated drug discovery and mechanistic studies. Inhibitors targeting PARVA-ILK interactions are being explored to suppress cancer metastasis. However, PARVA’s dual role as both a tumor suppressor and promoter in different contexts complicates therapeutic strategies, necessitating further research. Overall, recombinant PARVA serves as a vital tool for decoding its biological significance and developing targeted therapies for adhesion-related pathologies.
×
